FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024431383> ?p ?o ?g. }

• W2024431383 endingPage "2294" @default.
• W2024431383 startingPage "2285" @default.
• W2024431383 abstract "Whether prasugrel plus bivalirudin is a superior strategy to unfractionated heparin plus clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) has never been assessed in specifically designed randomized trials.The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 study is an investigator-initiated, randomized, open-label, multicentre trial, designed to test the hypothesis that in STEMI patients with planned primary PCI a strategy based on prasugrel plus bivalirudin is superior to a strategy based on clopidogrel plus heparin in terms of net clinical outcome. Owing to slow recruitment, the trial was stopped prematurely after enrolment of 548 of 1240 planned patients. At 30 days, the primary composite endpoint of death, myocardial infarction, unplanned revascularization of the infarct related artery, stent thrombosis, stroke, or bleeding was observed in 42 patients (15.6%) randomized to prasugrel plus bivalirudin and 40 patients (14.5%) randomized to clopidogrel plus heparin [relative risk, 1.09; one-sided 97.5% confidence interval (CI) 0-1.79, P = 0.680]. The composite ischaemic endpoint of death, myocardial infarction, unplanned revascularization of the infarct-related artery, stent thrombosis, or stroke occurred in 13 patients (4.8%) in the prasugrel plus bivalirudin group and 15 patients (5.5%) in the clopidogrel plus heparin group (relative risk, 0.89; 95% CI 0.40-1.96, P = 0.894). Bleeding according to the HORIZONS-AMI definition was observed in 38 patients (14.1%) in the prasugrel plus bivalirudin group and 33 patients (12.0%) in the clopidogrel plus heparin group (relative risk, 1.18; 95% CI 0.74-1.88, P = 0.543). Results were consistent across various subgroups of patients.In this randomized trial of STEMI patients, we were unable to demonstrate significant differences in net clinical outcome between prasugrel plus bivalirudin and clopidogrel plus heparin. Neither the composite of ischaemic complications nor bleeding were favourably affected by prasugrel plus bivalirudin compared with a regimen of clopidogrel plus unfractionated heparin. However, the results must be interpreted in view of the premature termination of the trial.Unique identifier NCT00976092 (www.clinicaltrials.gov)." @default.
• W2024431383 created "2016-06-24" @default.
• W2024431383 creator A5006952690 @default.
• W2024431383 creator A5015669756 @default.
• W2024431383 creator A5016139987 @default.
• W2024431383 creator A5021595862 @default.
• W2024431383 creator A5023042885 @default.
• W2024431383 creator A5024459238 @default.
• W2024431383 creator A5028965875 @default.
• W2024431383 creator A5039377663 @default.
• W2024431383 creator A5057534153 @default.
• W2024431383 creator A5064708989 @default.
• W2024431383 creator A5066812477 @default.
• W2024431383 creator A5070212671 @default.
• W2024431383 creator A5072633257 @default.
• W2024431383 creator A5073186317 @default.
• W2024431383 creator A5076687291 @default.
• W2024431383 creator A5079998960 @default.
• W2024431383 creator A5091776005 @default.
• W2024431383 date "2014-05-09" @default.
• W2024431383 modified "2023-10-08" @default.
• W2024431383 title "Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction" @default.
• W2024431383 cites W1540840894 @default.
• W2024431383 cites W159217275 @default.
• W2024431383 cites W2001942881 @default.
• W2024431383 cites W2016954112 @default.
• W2024431383 cites W2030271409 @default.
• W2024431383 cites W2055474976 @default.
• W2024431383 cites W2061381591 @default.
• W2024431383 cites W2073159589 @default.
• W2024431383 cites W2085869089 @default.
• W2024431383 cites W2087150869 @default.
• W2024431383 cites W2110108344 @default.
• W2024431383 cites W2116457054 @default.
• W2024431383 cites W2121251309 @default.
• W2024431383 cites W2140501627 @default.
• W2024431383 cites W2142825093 @default.
• W2024431383 cites W2153447053 @default.
• W2024431383 cites W2156927593 @default.
• W2024431383 cites W2166950143 @default.
• W2024431383 cites W2168874562 @default.
• W2024431383 cites W2169387542 @default.
• W2024431383 cites W81845835 @default.
• W2024431383 doi "https://doi.org/10.1093/eurheartj/ehu182" @default.
• W2024431383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24816809" @default.
• W2024431383 hasPublicationYear "2014" @default.
• W2024431383 type Work @default.
• W2024431383 sameAs 2024431383 @default.
• W2024431383 citedByCount "88" @default.
• W2024431383 countsByYear W20244313832014 @default.
• W2024431383 countsByYear W20244313832015 @default.
• W2024431383 countsByYear W20244313832016 @default.
• W2024431383 countsByYear W20244313832017 @default.
• W2024431383 countsByYear W20244313832018 @default.
• W2024431383 countsByYear W20244313832019 @default.
• W2024431383 countsByYear W20244313832020 @default.
• W2024431383 countsByYear W20244313832021 @default.
• W2024431383 countsByYear W20244313832022 @default.
• W2024431383 countsByYear W20244313832023 @default.
• W2024431383 crossrefType "journal-article" @default.
• W2024431383 hasAuthorship W2024431383A5006952690 @default.
• W2024431383 hasAuthorship W2024431383A5015669756 @default.
• W2024431383 hasAuthorship W2024431383A5016139987 @default.
• W2024431383 hasAuthorship W2024431383A5021595862 @default.
• W2024431383 hasAuthorship W2024431383A5023042885 @default.
• W2024431383 hasAuthorship W2024431383A5024459238 @default.
• W2024431383 hasAuthorship W2024431383A5028965875 @default.
• W2024431383 hasAuthorship W2024431383A5039377663 @default.
• W2024431383 hasAuthorship W2024431383A5057534153 @default.
• W2024431383 hasAuthorship W2024431383A5064708989 @default.
• W2024431383 hasAuthorship W2024431383A5066812477 @default.
• W2024431383 hasAuthorship W2024431383A5070212671 @default.
• W2024431383 hasAuthorship W2024431383A5072633257 @default.
• W2024431383 hasAuthorship W2024431383A5073186317 @default.
• W2024431383 hasAuthorship W2024431383A5076687291 @default.
• W2024431383 hasAuthorship W2024431383A5079998960 @default.
• W2024431383 hasAuthorship W2024431383A5091776005 @default.
• W2024431383 hasConcept C126322002 @default.
• W2024431383 hasConcept C127413603 @default.
• W2024431383 hasConcept C164705383 @default.
• W2024431383 hasConcept C2777028646 @default.
• W2024431383 hasConcept C2777565915 @default.
• W2024431383 hasConcept C2777849778 @default.
• W2024431383 hasConcept C2780400711 @default.
• W2024431383 hasConcept C2780645631 @default.
• W2024431383 hasConcept C42219234 @default.
• W2024431383 hasConcept C45393284 @default.
• W2024431383 hasConcept C500558357 @default.
• W2024431383 hasConcept C71924100 @default.
• W2024431383 hasConcept C78519656 @default.
• W2024431383 hasConceptScore W2024431383C126322002 @default.
• W2024431383 hasConceptScore W2024431383C127413603 @default.
• W2024431383 hasConceptScore W2024431383C164705383 @default.
• W2024431383 hasConceptScore W2024431383C2777028646 @default.
• W2024431383 hasConceptScore W2024431383C2777565915 @default.
• W2024431383 hasConceptScore W2024431383C2777849778 @default.
• W2024431383 hasConceptScore W2024431383C2780400711 @default.
• W2024431383 hasConceptScore W2024431383C2780645631 @default.

• next